NEVRO CORP. — Revenue by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/1a230768-3498-4a84-b6ac-c2f3f157de14/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2024 | $408.5M | 2024-01-01 – 2024-12-31 | evidence 0001444380-25-000024 |
| FY 2023 | $425.2M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-019464 |
| FY 2022 | $406.4M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-003296 |
| FY 2021 | $386.9M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-006312 |
| FY 2020 | $362.0M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-008153 |
| FY 2019 | $390.3M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-006427 |
| FY 2018 | $387.3M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-003708 |
| FY 2017 | $326.7M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-003708 |
| FY 2016 | $228.5M | 2016-01-01 – 2016-12-31 | evidence 0001564590-19-003708 |
| FY 2015 | $69.6M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-485541 |
| FY 2014 | $32.6M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-097120 |
| FY 2013 | $23.5M | 2013-01-01 – 2013-12-31 | evidence 0001193125-15-097120 |
| FY 2012 | $18.1M | 2012-01-01 – 2012-12-31 | evidence 0001193125-15-097120 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).